Sage Therapeutics
Manufacturing · Massachusetts, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
215 1st St, Cambridge, Massachusetts, 02...Phone Number
(617) 299-8380Website
www.sagerx.comRevenue
$41.2 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
3
1
1
1
1
1
About Sage Therapeutics
Founded in 2010 and headquartered in Cambridge, Massachusetts, Sage Therapeutics operates as a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous systems.Explore more
Sage Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Sage Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Sage Therapeutics launches new products
Click to see if Sage Therapeutics had a recent Job posting/layoffs
Check out if Sage Therapeutics is spiking on competitors!
Earning: See what the market has to say on Sage Therapeutics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Sage Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Sage Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Sage Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Sage Therapeutics
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Sage Therapeutics
Compare insights from companies similar to Sage Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Sage Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Sage Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Sage Therapeutics.
Sage Therapeutics financials insights
Gather financial insights about Sage Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2013
Series B
$20M
2014
Series C
$38M
Stock Offering
$103.5M
2015
Stock Offering
$138M
2016
Stock Offering
$150M
Stock Offering
$175M
2017
Stock Offering
$345M
2018
Stock Offering
$575M
2019
Stock Offering
$575M
Sage Therapeutics Tech Stack
A closer look at the technologies used by Sage Therapeutics
See more technologies
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Person-Based
Person-Based
Person-Based
Person-Based
Sage Therapeutics News & Media
Shareholder Alert: The Ademi Firm Investigates Whether Sage Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Sage (NASDAQ: SAGE) for possible breaches of fiduciary duty and other violations of law in its transaction with Supernus Pharmaceuticals. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the tender offer transaction, shareholders of Sage will receive $8.50 per share in cash (or an aggregate of apSupernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio
ROCKVILLE, Md. and CAMBRIDGE, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) and Sage Therapeutics, Inc. (Nasdaq: SAGE), today announced a definitive agreement for Supernus to acquire Sage through a tender offer for $8.50 per share in cash (or an aggregate of approximately $561 million), payable at closing, plus one non-tradable contingent value right (CVR) collectively worth up to $3.50 per share in cash (or an aggregate of approximately $234 million),Sage Therapeutics, Inc. (SAGE) Q1 2025 Earnings Call Transcript
Sage Therapeutics, Inc. (NASDAQ:SAGE) Q1 2025 Earnings Call April 29, 2025 4:30 PM ETCompany ParticipantsAshley Kaplowitz - Investor RelationsBarry Greene -...Sage Therapeutics Announces First Quarter 2025 Financial Results and Highlights Pipeline and Business Updates
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), today reported business highlights and financial results for the first quarter ended March 31, 2025. “We delivered strong growth in revenue and shipments of ZURZUVAE during the first quarter of 2025 through the team’s disciplined execution and unwavering commitment to bringing ZURZUVAE to more women with postpartum depression,” said Barry Greene, Chief Executive Officer at Sage Therapeutics. “We remain focused on establi
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Sage Therapeutics
Sign Up For FreeTo access detailed company insights
Founded in 2010 and headquartered in Cambridge, Massachusetts, Sage Therapeutics operates as a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous systems.... Read More
